The North America pharmacogenomics market is witnessing steady growth due to increasing adoption of personalized medicine, growing use of genetic information in drug selection and treatment decisions, and expanding applications of pharmacogenomic testing across healthcare. The North America pharmacogenomics market size was valued at USD 4.10 billion in 2025 and is projected to grow from USD 4.62 billion in 2026 to reach USD 11.93 billion by 2034, growing at a CAGR of 12.6% during the forecast period 2026–2034.
The market is expanding as healthcare providers, pharmaceutical companies, clinical laboratories, and research organizations increasingly use pharmacogenomic information to understand how genetic variations influence individual responses to medications. Advancements in genetic testing, sequencing technologies, clinical decision-support tools, and data interpretation are further supporting the integration of pharmacogenomics into clinical care, drug development, and personalized treatment strategies.
Market Drivers
One of the primary factors driving the North America pharmacogenomics market is the growing adoption of personalized medicine. Healthcare providers increasingly use genetic information to identify how patients may respond to specific medicines, which supports more individualized treatment decisions and can reduce the use of unsuitable therapies.
Another significant growth driver is the increasing application of pharmacogenomic testing in oncology. Genetic information can help healthcare professionals understand variations associated with drug response and support treatment selection for patients receiving targeted and other cancer therapies.
The expansion of clinical research on drug-gene associations is also contributing to market growth. Pharmaceutical companies, academic institutions, and healthcare organizations are generating additional evidence on how genetic variations affect medication response, creating opportunities for broader clinical use of pharmacogenomic testing.
Furthermore, advances in next-generation sequencing, genotyping technologies, bioinformatics, and genetic data interpretation are improving the ability of laboratories to analyze multiple drug-related genes. These technological developments are supporting broader testing applications across cardiovascular care, psychiatry, oncology, and other therapeutic areas.
Market Challenges
Despite favorable growth prospects, the North America pharmacogenomics market faces several challenges. One major challenge is the shortage of healthcare professionals with specialized knowledge in pharmacogenomic testing and interpretation, which can limit the integration of test results into routine clinical workflows.
Another challenge is the long turnaround time associated with certain genetic tests. Delays in receiving results can reduce the usefulness of pharmacogenomic information when treatment decisions need to be made quickly, particularly in acute or time-sensitive clinical settings.
Additionally, differences in clinical adoption, reimbursement coverage, data interpretation practices, and integration with electronic health records can create barriers to broader use. Healthcare providers may also require additional clinical evidence and workflow support before incorporating pharmacogenomic testing into routine prescribing decisions.
Market Segmentation
By Technology:
Microarray
Sequencing
Polymerase Chain Reaction (PCR)
Others
The microarray segment holds a significant market share due to its ability to analyze multiple genetic variants simultaneously and its established use in pharmacogenomic testing.
The sequencing segment represents an important area of adoption as advances in sequencing technologies support broader analysis of genetic variants associated with drug response.
By Application:
Oncology
Cardiovascular
Psychiatry
Pain Management
Others
The oncology segment represents a major application area due to the increasing use of genomic information to support personalized cancer treatment and understand patient responses to medications.
Cardiovascular applications are also supported by pharmacogenomic testing for medications where genetic variations can influence treatment response and dosing requirements.
Psychiatric applications include the use of genetic information to support medication selection and treatment strategies for patients receiving certain psychotropic medicines.
By End User:
Hospitals and Clinics
Research Institutions
Pharmaceutical Companies
Diagnostic Laboratories
Others
The hospitals and clinics segment accounts for a significant share due to the increasing integration of pharmacogenomic information into patient treatment and medication-management processes.
Diagnostic laboratories also play an important role by providing genetic testing, laboratory analysis, and pharmacogenomic reports to healthcare providers and patients.
Regional Insights
United States
The United States represents a significant market within North America due to its advanced healthcare infrastructure, extensive pharmaceutical industry, established clinical laboratory network, and growing adoption of precision medicine. Increasing research into drug-gene relationships and the use of genetic information in clinical decision-making continue to support pharmacogenomics adoption.
Canada
Canada represents an important market supported by its healthcare infrastructure, expanding precision-medicine research, and increasing interest in genomic testing. Research institutions, healthcare organizations, and diagnostic providers are contributing to the adoption of pharmacogenomic approaches in selected clinical applications.
Key Players Analysis
The North America pharmacogenomics market is competitive, with companies focusing on genetic testing technologies, clinical evidence, laboratory services, data interpretation, personalized reporting, and integration with healthcare workflows to strengthen their market positions. Key companies operating in the market include:
F. Hoffmann-La Roche Ltd.
QIAGEN
Thermo Fisher Scientific Inc.
Illumina, Inc.
Abbott Laboratories
Danaher Corporation
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Invitae Corporation
OneOme, LLC
These companies continue developing genetic testing platforms, pharmacogenomic panels, sequencing technologies, clinical decision-support capabilities, and laboratory services to address the growing use of genetic information in medication selection and personalized treatment across North America.
For Detailed Insights, Visit:
https://straitsresearch.com/report/north-america-pharmacogenomics-market
About Us
Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.
Contact Us
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
